LUMAKRAS Market Summary

Key Factors Driving LUMAKRAS Growth

1. Major expansion into KRAS G12C-mutated colorectal cancer: The biggest recent growth driver is the FDA approval in January 2025 of LUMAKRAS in combination with panitumumab for adults with KRAS G12C-mutated mCRC after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The approval was based on CodeBreaK 300, where sotorasib 960 mg + panitumumab produced median PFS of 5.6 months versus 2.2 months with investigator's-choice therapy (HR 0.49) and an ORR of 26.4% versus 0%. This creates a second commercially important tumor type for LUMAKRAS beyond NSCLC.

2. Large unmet need in refractory KRAS G12C-positive mCRC: KRAS G12C mutations occur in approximately 3% of colorectal cancers, and metastatic CRC has a poor prognosis, with a reported 5-year relative survival of only 15.7%. The FDA therefore recognizes KRAS G12C-mutated refractory CRC as a serious condition with limited treatment options. LUMAKRAS' ability to provide a biomarker-directed option after standard chemotherapy supports continued uptake in this population.

3. Combination with panitumumab improves the effectiveness of KRAS inhibition: LUMAKRAS' activity in CRC is strengthened by combining it with EGFR blockade. In CodeBreaK 300, the 960-mg combination more than doubled median PFS compared with investigator's choice, while the response rate was 26% versus 0%. Updated overall-survival analysis showed an OS HR of 0.70, although the study was not powered to demonstrate a statistically significant OS difference. These results support the combination as an important post-chemotherapy targeted-treatment option.

4. Established efficacy and durable responses in KRAS G12C-positive NSCLC: LUMAKRAS remains an established treatment for previously treated KRAS G12C-mutated advanced NSCLC. In the CodeBreaK 100 Phase II study, the ORR was 37.1%, median duration of response was 11.1 months, disease-control rate was 80.6%, and median overall survival was 12.5 months. A longer follow-up analysis reported an ORR of 40.7%, median PFS of 6.3 months, median OS of 12.5 months, and 32.5% of patients alive at two years.

5. Growing international contribution is supporting revenue: Amgen's actual sales data show particularly strong growth outside the U.S. In 2025, LUMAKRAS/LUMYKRAS generated $363 million globally, compared with $350 million in 2024, representing 4% growth. U.S. sales were essentially flat at $211 million versus $214 million in 2024, while ROW sales increased 12% to $152 million. Amgen attributed the 2025 full-year increase primarily to 13% volume growth, partially offset by lower net selling price. This suggests that geographic expansion and patient-volume growth remain important commercial drivers.

LUMAKRAS Recent Developments

In January 2025, Amgen announced that the US Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase III CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC).

“LUMAKRAS Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of LUMAKRAS for approved indication like Colorectal cancer and Non-small cell lung cancer; as well as potential indication like Solid tumours, Brain metastases, and Pancreatic cancer in the 7MM. A detailed picture of LUMAKRAS’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the LUMAKRAS for approved and potential indications. The LUMAKRAS market report provides insights about LUMAKRAS’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LUMAKRAS performance, future market assessments inclusive of the LUMAKRAS market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LUMAKRAS sales forecasts, along with factors driving its market.

LUMAKRAS Drug Summary

LUMAKRAS (Sotorasib) is an orally administered, small-molecule inhibitor of the KRAS G12C protein developed by Amgen for the treatment of cancers harboring the KRAS G12C mutation. By selectively and irreversibly binding to the cysteine residue created by the G12C mutation, sotorasib locks KRAS in an inactive state and suppresses downstream signaling pathways involved in tumor-cell proliferation and survival. LUMAKRAS is approved as a single agent for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy, and in combination with panitumumab for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The recommended dose is 960 mg orally once daily, with treatment continued until disease progression or unacceptable toxicity. Common adverse reactions include diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough in NSCLC, while combination treatment in colorectal cancer commonly causes rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain; important serious risks include hepatotoxicity and interstitial lung disease/pneumonitis. The report provides LUMAKRAS’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LUMAKRAS Market Report

The report provides insights into:

• A comprehensive product overview including the LUMAKRAS MoA, description, dosage and administration, research and development activities in approved indications like Colorectal cancer and Non-small cell lung cancer; as well as potential indication like Solid tumours, Brain metastases, and Pancreatic cancer.
• Elaborated details on LUMAKRAS regulatory milestones and other development activities have been provided in LUMAKRAS market report.
• The report also highlights LUMAKRAS‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The LUMAKRAS market report also covers the patents information, generic entry and impact on cost cut.
• The LUMAKRAS market report contains current and forecasted LUMAKRAS sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LUMAKRAS market report also features the SWOT analysis with analyst views for LUMAKRAS in approved and potential indications.

Methodology

The LUMAKRAS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUMAKRAS Analytical Perspective by DelveInsight

• In-depth LUMAKRAS Market Assessment

This LUMAKRAS sales market forecast report provides a detailed market assessment of LUMAKRAS for approved indication like Colorectal cancer and Non-small cell lung cancer; as well as potential indication like Solid tumours, Brain metastases, and Pancreatic cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LUMAKRAS sales data uptil 2034.

• LUMAKRAS Clinical Assessment

The LUMAKRAS market report provides the clinical trials information of LUMAKRAS for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

LUMAKRAS Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LUMAKRAS Market Potential & Revenue Forecast

• Projected market size for the LUMAKRAS and its key indications
• Estimated LUMAKRAS sales potential (LUMAKRAS peak sales forecasts)
• LUMAKRAS Pricing strategies and reimbursement landscape

LUMAKRAS Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LUMAKRAS Market positioning compared to existing treatments
• LUMAKRAS Strengths & weaknesses relative to competitors

LUMAKRAS Regulatory & Commercial Milestones

• LUMAKRAS Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LUMAKRAS Clinical Differentiation

• LUMAKRAS Efficacy & safety advantages over existing drugs
• LUMAKRAS Unique selling points

LUMAKRAS Market Report Highlights

• In the coming years, the LUMAKRAS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LUMAKRAS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUMAKRAS’s dominance.
• Other emerging products for Colorectal cancer and Non-small cell lung cancer; as well as potential indication like Solid tumours, Brain metastases, and Pancreatic cancer are expected to give tough market competition to LUMAKRAS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUMAKRAS in approved and potential indications.
• Analyse LUMAKRAS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LUMAKRAS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LUMAKRAS in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of LUMAKRAS? How strong is LUMAKRAS’s clinical and commercial performance?
• What is LUMAKRAS’s clinical trial status in each individual indications such as Colorectal cancer and Non-small cell lung cancer; as well as potential indication like Solid tumours, Brain metastases, and Pancreatic cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUMAKRAS Manufacturers?
• What are the key designations that have been granted to LUMAKRAS for approved and potential indications? How are they going to impact LUMAKRAS’s penetration in various geographies?
• What is the current and forecasted LUMAKRAS market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LUMAKRAS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LUMAKRAS for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is LUMAKRAS? What is the duration of therapy and what are the geographical variations in cost per patient?